VHIO’s Cancer Genomics Group serves as a Core Technology laboratory. We are also dedicated to translational research as well as the development of novel genomic tests.
Our group provides cutting-edge applications in cancer genomics through state-of-the-art technologies and we develop new, fully validated tests that are used in the clinical research setting. Our lab is equipped with an n-Counter (Nanostring) platform, two digital PCR platforms (BEAMing Sysmex and ddPCR, BIO-RAD) and five NextGen Sequencers; MiSeq, NextSeq, HiSeq2500 and NovaSeq6000 from Illumina, and a MinION from Oxford Nanopore Technologies.
Our lab completed the technology transfer of the Food and Drug Administration (FDA)-approved Guardant360® CDx liquid biopsy test for comprehensive genomic profiling. With this test, VHIO360, our Institute is the first cancer research center in Europe to have a laboratory equipped with this cutting-edge platform. Aimed at overcoming the limitations and challenges of tissue biopsies, this technology provides complete genomic results in all solid tumors from a simple blood draw in seven days.
Molecular Prescreening at VHIO is co-led by our group’s Principal Investigator, Ana Vivancos, alongside Paolo Nuciforo, Elena Garralda, and Rodrigo Dienstmann, Principal Investigators of our Molecular Oncology, Early Clinical Drug Development, and Oncology Data Science – OdysSey Groups, respectively. Supported through our institutional Advanced Molecular Diagnostics Program (DIAMAV), powered by the Fundación FERO, we perform molecular profiling in over 1100 patients each year as potential candidates for enrollment in our phase I clinical trials led by VHIO’s Research Unit for Molecular Therapy of Cancer (UITM) – CaixaResearch, directed by Elena Garralda. Patients’ suitability for inclusion in any given clinical study is assessed based on their respective genomic profile and pathologic features.
Company Details
- Employees
- 2
- Founded
- -
- Address
- Carrer De Natzaret, 115,spain
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- The Maus Lab.
- HQ
- Barcelona, Catalunya
Cancer Genomics Lab - Vhio Questions
Cancer Genomics Lab - Vhio's website is https://vhio.net/pf/cancer-genomics-group/
Cancer Genomics Lab - Vhio's LinkedIn profile is https://es.linkedin.com/company/cancer-genomics-group
Cancer Genomics Lab - Vhio has
2 employees.
View email and phone details for 2
employees at Cancer Genomics Lab - Vhio.
Cancer Genomics Lab - Vhio's industry is
Biotechnology Research
Cancer Genomics Lab - Vhio's top competitors are
Reveal Genomics,
Irb Barcelona,
Cancer Genomics Consortium,
Airc - Foundation For Cancer Research Ngo,
Bgi Genomics,
Carreras Leaders,
The Maus Lab,
Vall D'hebron Institute Of Oncology (Vhio),
Hospital General De Granollers,
Roche.
Cancer Genomics Lab - Vhio's categories are Biotechnology Research
Cancer Genomics Lab - Vhio's founding year is 2003
